Pacer Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History

Pacer Advisors, Inc.

$41.8 Billion
Q3 2024

A detailed history of Pacer Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Pacer Advisors, Inc. holds 32,441 shares of VRTX stock, worth $14.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

32,441

Previous 38,326 15.36%

Holding current value

$14.6 Million

Previous $18 Million 16.02%

% of portfolio

0.04%

Previous 0.05%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$460.0 - $505.78 $2.71 Million - $2.98 Million	-5,885 Reduced 15.36%	32,441 $15.1 Million
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $426,198 - $526,800	1,085 Added 2.91%	38,326 $18 Million
Q1 2024 May 10, 2024	SELL	$407.69 - $446.08 $1.64 Million - $1.79 Million	-4,011 Reduced 9.72%	37,241 $15.6 Million
Q4 2023 Jan 16, 2024	BUY	$343.0 - $410.68 $4.1 Million - $4.9 Million	11,940 Added 40.73%	41,252 $16.8 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $1.19 Million - $1.27 Million	3,510 Added 13.6%	29,312 $10.2 Million
Q2 2023 Jul 12, 2023	SELL	$314.42 - $351.91 $3.69 Million - $4.13 Million	-11,750 Reduced 31.29%	25,802 $9.08 Million
Q1 2023 May 02, 2023	BUY	$283.23 - $323.1 $6.48 Million - $7.39 Million	22,887 Added 156.07%	37,552 $11.8 Million
Q4 2022 Feb 06, 2023	BUY	$285.76 - $321.48 $1.27 Million - $1.43 Million	4,439 Added 43.41%	14,665 $4.23 Million
Q3 2022 Oct 18, 2022	BUY	$273.83 - $305.53 $16,703 - $18,637	61 Added 0.6%	10,226 $2.96 Million
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $681,618 - $848,687	-2,901 Reduced 22.2%	10,165 $2.86 Million
Q1 2022 Apr 05, 2022	SELL	$221.42 - $260.97 $1.86 Million - $2.19 Million	-8,387 Reduced 39.09%	13,066 $3.41 Million
Q4 2021 Feb 03, 2022	SELL	$177.01 - $223.45 $1.32 Million - $1.66 Million	-7,435 Reduced 25.74%	21,453 $4.71 Million
Q3 2021 Oct 15, 2021	BUY	$181.39 - $202.99 $352,803 - $394,815	1,945 Added 7.22%	28,888 $5.24 Million
Q2 2021 Jul 21, 2021	BUY	$187.49 - $221.1 $528,721 - $623,502	2,820 Added 11.69%	26,943 $5.43 Million
Q1 2021 Apr 05, 2021	SELL	$207.02 - $241.31 $438,468 - $511,094	-2,118 Reduced 8.07%	24,123 $5.18 Million
Q4 2020 Jan 20, 2021	SELL	$207.01 - $276.09 $2.54 Million - $3.38 Million	-12,246 Reduced 31.82%	26,241 $6.2 Million
Q3 2020 Oct 19, 2020	SELL	$255.65 - $303.1 $1.36 Million - $1.61 Million	-5,313 Reduced 12.13%	38,487 $10.5 Million
Q2 2020 Jul 29, 2020	BUY	$225.48 - $295.8 $5.17 Million - $6.78 Million	22,933 Added 109.9%	43,800 $12.7 Million
Q1 2020 Apr 23, 2020	BUY	$199.77 - $247.81 $122,059 - $151,411	611 Added 3.02%	20,867 $5.64 Million
Q4 2019 Feb 10, 2020	SELL	$166.71 - $223.91 $4.43 Million - $5.96 Million	-26,602 Reduced 56.77%	20,256 $4.44 Million
Q3 2019 Oct 10, 2019	BUY	$166.23 - $187.09 $939,199 - $1.06 Million	5,650 Added 13.71%	46,858 $7.94 Million
Q2 2019 Aug 12, 2019	BUY	$164.61 - $190.37 $667,987 - $772,521	4,058 Added 10.92%	41,208 $7.56 Million
Q1 2019 Apr 10, 2019	BUY	$163.73 - $194.7 $6.08 Million - $7.23 Million	37,150 New	37,150 $6.83 Million
Q4 2018 Feb 13, 2019	SELL	$151.91 - $192.21 $3.81 Million - $4.82 Million	-25,079 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$167.73 - $192.74 $847,371 - $973,722	5,052 Added 25.23%	25,079 $4.83 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $525,466 - $612,875	3,606 Added 21.96%	20,027 $3.4 Million
Q1 2018 May 14, 2018	BUY	$151.6 - $177.13 $330,336 - $385,966	2,179 Added 15.3%	16,421 $2.68 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $810,501 - $918,367	5,904 Added 70.81%	14,242 $2.13 Million
Q3 2017 Nov 08, 2017	BUY	$148.13 - $162.24 $1.24 Million - $1.35 Million	8,338	8,338 $1.27 Million

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pacer Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pacer Advisors, Inc. with notifications on news.

Account

Pacer Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History